Related Substances Testing for Pharmaceutical Preparations: Methods, Standards, and Applications

Related substances testing is a critical quality control procedure for pharmaceutical preparations, designed to detect and quantify degradation products and process-related organic impurities in finished dosage forms. This testing safeguards patient safety, demonstrates regulatory compliance with ICH guidelines, and confirms that a drug product remains within approved impurity limits throughout its shelf life. This article outlines the technical principles, sample types, testing items, analytical methods, and practical applications of related substances testing for pharmaceutical preparations.

Technical Overview

Related substances, also known as related compounds or organic impurities, are chemical entities present in a finished pharmaceutical preparation other than the active pharmaceutical ingredient (API) and its intended excipients. In drug products, these impurities primarily arise from degradation of the active ingredient during manufacturing, storage, or distribution. Common degradation pathways include hydrolysis, oxidation, photolysis, thermal decomposition, and drug–excipient interactions, while residual process-related impurities from the API may also carry over into the final preparation.

The regulatory framework for related substances in drug products is established by ICH Q3B(R2), which defines reporting, identification, and qualification thresholds based on the maximum daily dose of the active ingredient. For products with a maximum daily dose of 1 g or less, the reporting threshold is typically 0.1%; for higher doses, it is 0.05%. Identification and qualification requirements follow dose-banded scales, generally ranging from approximately 0.15% to 1.0%, with more stringent absolute limits applied to low-dose products. Mutagenic impurities are additionally controlled under ICH M7, and strategies for analytical method development are guided by ICH Q2(R2). A properly designed related substances method must be stability-indicating, meaning it must separate the API from all potential degradation products without interference from excipients.

Testing Samples

Solid Oral Dosage Forms

Tablets, capsules, granules, powders, and sachets represent the largest category of preparations submitted for related substances testing. Samples are typically ground or disintegrated, and the API together with its impurities is extracted using a suitable diluent, often with sonication or shaking, followed by centrifugation or filtration prior to injection.

Sterile and Parenteral Preparations

Injectable solutions, lyophilized powders for reconstitution, and large-volume infusions usually require minimal sample preparation, as the matrix is relatively clean. These products receive particular attention because impurities such as degradation products or leachables from packaging components are introduced directly into the systemic circulation.

Liquid and Semisolid Preparations

Oral solutions, syrups, suspensions, ophthalmic and otic drops, creams, ointments, and gels are tested using matrix-appropriate extraction and dilution procedures. Semisolid dosage forms often require solvent extraction to separate the API fraction from lipophilic excipient matrices before chromatographic analysis.

Specialized Delivery Systems

Inhalation products, transdermal patches, implants, and modified-release formulations are tested with tailored procedures that account for their unique matrices and release mechanisms. These products frequently demand additional method development to achieve adequate recovery and chromatographic resolution.

Testing Items

A comprehensive related substances testing program for pharmaceutical preparations typically includes the following items:

• Specified known impurities: structurally characterized impurities listed in the approved specification or pharmacopoeial monograph, each with an individual acceptance limit.
• Unspecified (unknown) impurities: chromatographic peaks that are not structurally identified, controlled by a general limit, commonly at the identification threshold.
• Total related substances: the sum of all individual impurity levels, controlled by an overall limit.
• Degradation products: impurities specifically formed through chemical or physical degradation of the API in the finished product.
• Enantiomeric impurities: chiral-related substances relevant for optically active drug substances, analyzed by chiral chromatography.
• Drug–excipient interaction products: adducts or reaction products formed between the API and functional excipients or packaging components.
• Genotoxic and nitrosamine impurities: evaluated where structural alerts or regulatory risk assessments indicate potential concern.

Testing Methods

High-Performance Liquid Chromatography (HPLC)

Reversed-phase HPLC with UV or diode-array detection (HPLC-UV/DAD) is the industry-standard technique for related substances testing. Gradient elution methods, using C18 or phenyl-hexyl columns with acidified aqueous and organic mobile phases, provide the resolution needed to separate the API from closely eluting impurities. DAD detection enables peak purity assessment through spectral analysis.

Ultra-High-Performance Liquid Chromatography (UHPLC)

UHPLC employs sub-2-micron particles to deliver higher resolution, shorter run times, and improved sensitivity, making it particularly valuable for complex impurity profiles and high-throughput quality control laboratories.

LC-MS/MS and High-Resolution Mass Spectrometry

When unknown impurities exceed identification thresholds, LC-MS/MS and LC-HRMS are used to determine molecular weight, fragmentation behavior, and proposed structures. This structural elucidation is essential for impurity qualification and for establishing scientifically justified specifications.

Method Development, Forced Degradation, and Validation

Stability-indicating methods are established through forced degradation studies, in which the product is stressed under acidic, basic, oxidative, thermal, humidity, and photolytic conditions consistent with ICH Q1A(R2). Candidate methods are then validated in accordance with ICH Q2(R2) for specificity, linearity, range, accuracy, precision, detection limit, quantitation limit, robustness, and solution stability. Pharmacopoeial methods from USP, EP, or JP monographs are verified for suitability in the specific sample matrix before use.

Supporting Techniques

Gas chromatography (GC or GC-MS) is applied to volatile impurities, capillary electrophoresis serves as an orthogonal separation technique for polar or ionic impurities, and chiral HPLC is used to resolve enantiomeric impurities. Wherever feasible, orthogonal methods are employed to confirm that no impurity co-elutes with the principal peak.

Applications

Related substances testing supports the pharmaceutical product lifecycle at multiple stages:

• Batch release: verifying that every commercial batch meets its approved impurity specification before distribution.
• Stability studies: monitoring impurity growth under long-term, intermediate, and accelerated storage conditions defined by ICH Q1A(R2), as well as photostability testing per ICH Q1B, to establish and confirm shelf life and storage conditions.
• Formulation development: comparing candidate formulations, screening excipient compatibility, and selecting the most stable composition.
• Post-approval changes: demonstrating comparability after changes in formulation, manufacturing site, process scale, or packaging components.
• Regulatory submissions: generating impurity data for CTD Module 3.2.P.5 in marketing authorization applications and variations.
• Packaging selection: evaluating container-closure systems for compatibility and leachables-related impurity risks.
• Investigations: supporting root-cause analysis of out-of-specification or out-of-trend impurity results in quality investigations.

FAQ

What is the difference between related substances testing for a drug substance and a drug product?

Drug substance testing (guided by ICH Q3A) focuses on process-related impurities from synthesis, whereas drug product testing (guided by ICH Q3B) emphasizes degradation products formed during manufacturing and storage, including impurities generated by drug–excipient interactions. Sample preparation for finished preparations must also address interference from the formulation matrix.

How much sample is required for testing?

Typical requirements range from a few units to several dozen units of the finished product, depending on the dosage form, the number of methods to be performed, and any repeat or confirmatory testing. Lyophilized or low-strength products may require additional units to achieve adequate analytical concentration.

How long does related substances testing take?

Routine testing using an established, validated method is generally completed within five to ten working days, including sample preparation, duplicate injections, and reporting. Method development, forced degradation studies, and full validation programs typically require several weeks to a few months.

Can testing be performed for products without a pharmacopoeial monograph?

Yes. Accredited third-party laboratories routinely develop and validate stability-indicating HPLC or UHPLC methods tailored to the specific product, impurity profile, and matrix, with limits justified according to ICH Q3B(R2) and available qualification data.

How are unknown impurities handled?

Unknown impurities exceeding the reporting threshold are quantified and reported against the unspecified impurity limit. If a peak exceeds the identification threshold, LC-MS/MS or LC-HRMS is used for structural elucidation, after which the impurity is qualified toxicologically and assigned a specific acceptance criterion.

What acceptance criteria are typically applied?

Acceptance criteria are product-specific and derive from pharmacopoeial monographs, the approved marketing authorization, or ICH Q3B(R2) thresholds. Typical specifications limit individual unspecified impurities at approximately 0.1% to 0.2% and total related substances at approximately 0.5% to 1.0%, although limits vary considerably with daily dose and safety data.